Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background Diabetes is one of the leading causes of death and disability worldwide, and
affects people regardless of country, age group, or sex. Using the most recent evidentiary …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Non-nutritive sweeteners (NNS) are commonly integrated into human diet and presumed to
be inert; however, animal studies suggest that they may impact the microbiome and …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Type 2 Diabetes Mellitus (T2DM), one of the most common metabolic disorders, is caused
by a combination of two primary factors: defective insulin secretion by pancreatic β-cells and …

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …